Centessa (CNTA) | Stock Overview & Key Data
Centessa Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $26.90 on June 14, 2021
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Financial Highlights
Profitability
Returns and Earnings
Growth
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Centessa CNTA | 1.66B Small-cap | 2.96% | 13.57% | 26.61% | -15.78% | -22.51% | 38.13% | 161.42% | -37.38% |
| Vertex VRTX | 114.06B Large-cap | 3.14% | 4.53% | -1.27% | 13.16% | 14.93% | -6.00% | 56.88% | 55.98% |
| Regeneron REGN | 55.27B Large-cap | 2.40% | 5.82% | -1.63% | -25.33% | -23.41% | -51.08% | -11.43% | -16.45% |
| Vera Therapeutics VERA | 1.38B Small-cap | 0.00% | 3.65% | 21.95% | -45.48% | -45.50% | -37.27% | 44.01% | 99.74% |
| Immunocore Holdings IMCR | 1.56B Small-cap | 1.34% | -7.73% | 35.67% | 10.09% | 11.60% | -17.97% | -25.06% | -24.98% |
| Agios AGIO | 1.93B Small-cap | 5.56% | 7.78% | 47.90% | 1.06% | 13.94% | -23.26% | 57.82% | -34.32% |
Ownership & Short Interest
Centessa Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Centessa would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
What is CNTA's 52-week high and low?
In the last 52 weeks, Centessa reached a high of $19.09 (on February 7, 2025) and a low of $9.00 (on July 22, 2024).
What is the market cap and P/E ratio for CNTA?
Curious about Centessa's size and valuation? Its market capitalization stands at 1.66B. When it comes to valuation, the P/E ratio (trailing twelve months) is -6.31, and the forward P/E (looking ahead) is -7.27.
Does CNTA pay dividends? If so, what's the yield?
As for dividends, Centessa isn't currently offering a significant yield, or that specific data isn't available right now.
Who are Centessa's main competitors or similar companies to consider before investing?
When looking at Centessa, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
| Company | Mkt Cap | Sector | Industry | 1Y Return | 3Y Return |
|---|---|---|---|---|---|
| Vertex VRTX | 114.06B | Healthcare | Biotechnology | -6.00% | 56.88% |
| Regeneron REGN | 55.27B | Healthcare | Biotechnology | -51.08% | -11.43% |
| Vera Therapeutics VERA | 1.38B | Healthcare | Biotechnology | -37.27% | 44.01% |
| Immunocore Holdings IMCR | 1.56B | Healthcare | Biotechnology | -17.97% | -25.06% |
| Agios AGIO | 1.93B | Healthcare | Biotechnology | -23.26% | 57.82% |
For a more comprehensive list, please see the Peer Performance Comparison table on this page.
What are the key financial health indicators for Centessa Pharmaceuticals plc - ADR? (e.g., ROE, Debt/Equity)
To get a sense of Centessa's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -74.44%, the Debt to Equity ratio from the most recent quarter is 30.55, and its Gross Profit Margin stands at N/A.
What is the recent revenue and earnings growth for CNTA?
Looking at Centessa's growth, its revenue over the trailing twelve months (TTM) was $15M. Compared to the same quarter last year (YoY), quarterly revenue grew by N/A, and quarterly earnings saw a YoY growth of N/A.
How much of CNTA stock is held by insiders and institutions?
Wondering who owns Centessa stock? Company insiders (like executives and directors) hold about 0.34% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 96.61%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.